BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38653236)

  • 41. Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma.
    Galanis E; Wen PY; de Groot JF; Weller M
    Hematol Oncol Clin North Am; 2022 Feb; 36(1):113-132. PubMed ID: 34756799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
    Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
    Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of isocitrate dehydrogenase in glioma.
    Alexander BM; Mehta MP
    Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages.
    Dong M; Zhang X; Peng P; Chen Z; Zhang Y; Wan L; Xiang W; Liu G; Guo Y; Xiao Q; Wang B; Guo D; Zhu M; Yu X; Wan F
    Cancer Lett; 2024 May; 590():216801. PubMed ID: 38479552
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin.
    Raghavan JV; Ganesh RA; Sonpatki P; Naik D; John AE; Arunachalam P; Shah D; P S H; Lakshmikantha A; Pillai S; Chandrachari KP; Mariswamappa K; Lale S; Shah N; Jhunjhunwala S
    Oncoimmunology; 2021; 10(1):1957215. PubMed ID: 34377594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
    Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
    Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
    Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
    Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
    Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
    PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas.
    Berens ME; Sood A; Barnholtz-Sloan JS; Graf JF; Cho S; Kim S; Kiefer J; Byron SA; Halperin RF; Nasser S; Adkins J; Cuyugan L; Devine K; Ostrom Q; Couce M; Wolansky L; McDonough E; Schyberg S; Dinn S; Sloan AE; Prados M; Phillips JJ; Nelson SJ; Liang WS; Al-Kofahi Y; Rusu M; Zavodszky MI; Ginty F
    PLoS One; 2019; 14(12):e0219724. PubMed ID: 31881020
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
    Björkblom B; Wibom C; Eriksson M; Bergenheim AT; Sjöberg RL; Jonsson P; Brännström T; Antti H; Sandström M; Melin B
    Neuro Oncol; 2022 Sep; 24(9):1454-1468. PubMed ID: 35157758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis.
    Gollapalli K; Ghantasala S; Atak A; Rapole S; Moiyadi A; Epari S; Srivastava S
    OMICS; 2017 May; 21(5):275-284. PubMed ID: 28481733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IDH1
    Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
    Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
    Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
    Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.